ziprasidone + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Borderline Personality Disorder

Conditions

Borderline Personality Disorder

Trial Timeline

Mar 1, 2004 → Apr 1, 2006

NCT ID

NCT00635921

About ziprasidone + Placebo

ziprasidone + Placebo is a phase 2 stage product being developed by Pfizer for Borderline Personality Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00635921. Target conditions include Borderline Personality Disorder.

What happened to similar drugs?

0 of 4 similar drugs in Borderline Personality Disorder were approved

Approved (0) Terminated (0) Active (4)

🔄Olanzapine + placeboEli LillyPhase 3

🔄OlanzapineEli LillyPhase 3

🔄quetiapine extended-release + PlaceboAstraZenecaPhase 3

🔄Quetiapine FumarateAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03768726	Phase 3	Terminated	Dec 21, 2018	Jul 31, 2020	Bipolar Disorder
NCT01172652	Approved	Completed	Apr 1, 2010	Oct 1, 2011	Bipolar Disorder
NCT00483548	Phase 3	Completed	Oct 1, 2007	Dec 1, 2008	Bipolar Disorder
NCT00374543	Approved	Terminated	Feb 1, 2006	Nov 1, 2008	Generalized Anxiety Disorder
NCT00635921	Phase 2	Completed	Mar 1, 2004	Apr 1, 2006	Borderline Personality Disorder

Competing Products

12 competing products in Borderline Personality Disorder

See all competitors

Product	Company	Stage	Hype Score
Olanzapine + placebo	Eli Lilly	Phase 3	40
olanzapine	Eli Lilly	Pre-clinical	26
Olanzapine	Eli Lilly	Phase 3	40
Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab + Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate	Jiangsu Hengrui Medicine	Phase 2	31
Durvalumab + Tremelimumab + Gemcitabine + Cisplatin	AstraZeneca	Phase 2	27
quetiapine extended-release + Placebo	AstraZeneca	Phase 3	40
Quetiapine fumarate + Placebo	AstraZeneca	Phase 2	35
Quetiapine Fumarate	AstraZeneca	Phase 3	40
Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin	Bristol Myers Squibb	Phase 1	29
PD-1/PD-L1 inhibitors + Chemotherapy	BeOne Medicines	Phase 2	36
Fluorouracil + Irinotecan + Leucovorin + Leucovorin Calcium + Oxaliplatin + Quemliclustat + Zimberelimab	Arcus Biosciences	Phase 1/2	33
vafidemstat + Placebo	Oryzon Genomics	Phase 2	25